Solutions
New Imaging Biomarkers
Siena Imaging is aware of the impact that new biomarkers have in clinical trials. The use of new indices makes it possible to explain pathological mechanisms that are not yet fully understood and to improve the evaluation of drug efficacy. More reliable measures allow a better assessment of drug efficacy. The Siena Imaging research group implements a strategy consisting of 2 different stages, as shown below.
DEVELOPMENT OF NEW IMAGING BIOMARKERS THROUGH SELF-FUNDING AND NATIONAL OR INTERNATIONAL RESEARCH GRANTS.
Siena Imaging is currently engaged in the ideation and development of new analysis procedures able to better stratify the damage occurring in multiple sclerosis, Alzheimer’s disease and brain tumors, both at group and individual patient level.
APPLICATION OF NEW DEVELOPED BIOMARKERS IN POST-HOC ANALYSES SPONSORED BY PHARMACEUTICAL COMPANIES
The developed biomarkers are then tested and validated in post-hoc analyses using images previously collected in clinical trials to fully understand the additional information these new indices bring to disease understanding and patient monitoring.
The development cycle ends with the addition of the new biomarkers to the CRO’s imaging portfolio.